Brandt Peter C. 4

What Happened

• Peter C. Brandt, a director of IN8BIO, was granted a derivative award covering 22,000 shares (Form 4 filed 2026-05-12 reporting a 2026-05-09 grant). The filing reports $0.00 per share and a total reported value of $0, indicating this was a compensation award/derivative grant rather than an open-market purchase.

Key Details

• Transaction date: May 9, 2026; Form 4 filed: May 12, 2026.
• Transaction type: Grant / award of derivative securities (code A on the Form 4).
• Shares/units involved: 22,000 shares; reported price: $0.00; reported total value: $0.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Vesting: Footnote states 1/12 of the award vests in equal monthly installments beginning June 9, 2026, but the award will be fully vested by the company’s next annual meeting of stockholders if the director continues service through those dates.
• No indication in the excerpt that shares were sold or immediately exercised.

Context

• This is a compensation/derivative award subject to vesting, not an open-market purchase or sale. Such grants are common for directors as part of compensation and do not by themselves indicate a buy/sell sentiment. The vesting schedule means the economic benefit is tied to continued service through monthly installments and the next annual meeting.